IL1B and COVID-19: The reported improved outcomes in COVID-19 patients with higher levels of inflammatory markers such as suPAR and CRP after treatment with anakinra may therefore reflect favorable impacts of IL-1 blockade on IFN-γ activation and/or IFN-γ effector responses.